Andrew L. Sochacki, MD

Malignant Hematology Blog Banner

Breaking Barriers in Blood Cancer Treatment: Insights on the Future of Malignant Hematology

A recent START webinar titled Malignant Hematology: Advancing Treatment in Blood Cancers, provided an in-depth look into the current advancements and challenges in treating hematological malignancies. Moderated by Dr. Andrew Sochacki, Associate Director for Hematology and Clinical Research at START Midwest, the session brought together leading experts to discuss myeloid malignancies, lymphoid malignancies, plasma cell

Breaking Barriers in Blood Cancer Treatment: Insights on the Future of Malignant Hematology Read More »

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts) Read More »